A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated

Inclusion Criteria:

1. Patients volunteered to participate in this study and signed the informed consentform.
2. Age≥18 years old, no gender limitation.
3. Patient has a diagnosis of primary AML or AML secondary to myelodysplastic syndrome (MDS) as determined by pathological and morphological results, according to WorldHealth Organization (WHO) 2016 classification.
4. Patient is refractory to or relapsed after first-line AML therapy (with or withoutHSCT).
5. Refractory to first-line AML treatment is defined as: the patient did not achievecomplete remission/complete remission with incomplete hematologicrecovery/complete remission with incomplete platelet recovery (CR/CRi/CRp) underinitial therapy. A patient eligible for standard therapy must receive at least 1cycle of an anthracycline containing induction therapy in the standard dose forthe selected induction regimen. A patient not eligible for standard therapy musthave received at least 1 complete block of induction therapy seen as the optimumchoice of therapy to induce remission for this patient as per investigator'sassessment.
6. Early relapse after first-line AML therapy is defined as: the patients achievedCR/CRi/CRp after first-line treatment, and relapsed within 6 months withhematological relapse.
7. Advanced relapse after first-line AML therapy is defined as: the patientsachieved CR/CRi/CRp after first-line treatment and relapsed after 6 months withhematological relapse;
8. Patient is positive for FLT3 mutation in bone marrow or whole blood.
9. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
10. Patient is eligible for pre-selected salvage chemotherapy according to investigatorassessment.
11. Patient must meet the following criteria as indicated on the clinical laboratorytests:
12. Serum aspartate aminotransferase and alanine aminotransferase ≤ 3.0 x upper limitof normal (ULN);
13. Serum total bilirubin ≤ 1.5 x ULN;
14. Serum creatinine ≤ 3.0 x ULN or an estimated glomerular filtration rate of > 30mL/min.
15. Patient is suitable for oral administration of the study drug.
16. Female or male patient of childbearing age agree to take effective non-drugcontraception from the date of signing an informed consent to 180 days after the lastdose and will not donate sperm or eggs.

Exclusion Criteria:

1. Patient was diagnosed as acute promyelocytic leukemia (APL), or BCR-ABL-positiveleukemia (chronic myelogenous leukemia in blast crisis).
2. Patient has AML secondary to prior chemotherapy for other neoplasms (except for MDS).
3. AML with central nervous system (CNS) involvement (defined as highly suspected CNSinvolvement with clinical symptoms supported by imaging evidence).
4. Refractory hypokalemia or hypomagnesemia that is difficult to be corrected bysymptomatic treatment and has recurred in the past.
5. Patient is currently suffering from clinically significant graft-versus-host disease (GVHD) or receiving systemic cortisol hormone therapy for GVHD.
6. Patient has been previously diagnosed with another malignancy (except in the followingcases: disease-free for at least 5 years; Patients with treated nonmelanoma skincancer, breast in situ carcinoma or cervical intraepithelial neoplasia [regardless ofdisease status]; Localized prostate cancer with no recurrence or progression that isexpected to be cured after treatment, such as radiotherapy or surgery)
7. Patient has clinically significant abnormality of coagulation profile, such asdisseminated intravascular coagulation (DIC), hemophilia A, hemophilia B, and vonWillebrand disease.
8. Patient has had major surgery within 4 weeks prior to the study (the definition ofmajor surgery was based on the level 3 and level 4 surgeries stipulated in theManagement Measures for Clinical Application of Medical Technology), or has not fullyrecovered from any previous invasive operation.
9. Patient has radiation therapy within 4 weeks before the first study dose.
10. Patient has congestive heart failure New York Heart Association (NYHA) class 3 or 4 orpatient with a history of congestive heart failure NYHA class 3 or 4 in the past,unless a screening echocardiogram performed within 1 month before study entry resultsin a left ventricular ejection fraction that is ≥ 45%.
11. Patient has bradycardia and heart rate is less than 50 beats/min, except for pacemakeruser.
12. Patients with mean value of triplicate Fridericia-corrected QT interval (QTcF) in thescreening period, male > 450 ms, female > 470 ms.
13. Patients with diagnosed or suspected long QT syndrome at screening (including a familyhistory of long QT syndrome).
14. Patients with second degree (Mobitz II) or third degree atrioventricular block disease (except for patients who use the pacemaker).
15. Patients with uncontrolled angina or myocardial infarction in 6 months beforescreening.
16. Patient has a complete left bundle branch block during screening.
17. Patients with new clinically significant arrhythmias (except for sinus tachycardiacaused by anemia, infection and AML) or patients with previous arrhythmias thatrequire long-term use of drugs with QT-prolonging effects.
18. Patient has an active uncontrolled infection.
19. Patients are hepatitis B surface antigen-positive or have a history of hepatitis B,with HBV-DNA ≥2000 IU/mL in the past 3 months; Patients are hep
20. Patients with positive anti-human immunodeficiency virus antibodies or anti-Treponemapallidum specific antibodies.
21. Patient has cytotoxic chemotherapy drugs <2 weeks, or non-cytotoxic drugs <5half-lives prior to the first study dose (except hydroxyurea and other treatments usedto control hyperleucocytosis).
22. Patients have taken CYP 2C8 and CYP 3A4 strong inducers or inhibitors within 2 weeksprior to the first study dose.
23. Patients have previously received other FLT3 inhibitors (Gilteritinib, Quizatinib,Crenolanib, etc.), except for sorafenib.
24. Pregnant (blood pregnancy test positive in screening period) and lactating Female.
25. Patients are not suitable for the study in the investigator's opinion.